Navigation Links
Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions
Date:4/7/2011

y lead to discontinuation of CUVPOSA™. CUVPOSA™ may present abdominal distention, pain, nausea, or vomiting. It is important for physicians to assess patients for constipation, particularly within four to five days of initial dosing or after a dose increase. Diarrhea associated with CUVPOSA™ may be an early symptom of incomplete mechanical intestinal obstruction especially in patients with ileostomy or colostomy. If obstruction is suspected, discontinue CUVPOSA™.

Avoid patient exposure to high ambient temperatures.  Heat prostration (fever and heat stroke due to decreased sweating) can occur with use of anticholinergic drugs such as CUVPOSA™.

Patients should not engage in age-appropriate activities requiring mental alertness such as operating a motor vehicle or other machinery or perform hazardous work, as CUVPOSA™ may cause drowsiness or blurred vision.

Use CUVPOSA™ with caution in patients with conditions that are exacerbated by anticholinergic drug effects including:

  • Autonomic neuropathy, renal disease and ulcerative colitis. (Large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason, may precipitate or aggravate "toxic megacolon," a serious complication of the disease.)
  • Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension, and hiatal hernia associated with reflux esophagitis.

Glycopyrrolate reduces GI transit time which may result in altered release of certain drugs when formulated in delayed or controlled-release forms. CUVPOSA™ can increase serum levels of atenolol, metformin and digoxin (slow dissolution tablets; consider other dosage forms of digoxin). Dose reductions of atenolol or metformin may be needed.

CUVPOSA™ may decrease serum levels of haloperidol or levodopa. Consider dose i
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
2. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
3. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
6. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
7. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
8. Mtech Announces Finalists for University of Maryland $75K Business Plan Competition
9. Caliper Life Sciences Announces Date and Location of its 2011 Annual Meeting of Stockholders
10. Kimberly-Clark Health Care Announces Strategic Green Partnerships, Commitment to Reducing Medical Waste
11. Dendreon Announces Presentation of Data at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PARK, N.J. , July 30, 2015  Unichem ... voluntarily recalling one lot of Hydrochlorothiazide tablets 25 mg ... been initiated as a precautionary measure due to the ... of the product. The risk associated ... Hydrochlorothiazide tablet is the increased probability of experiencing Clopidogrel,s ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... MUNDELEIN, Ill. , July 1 ... and information systems developer, today announces executive changes in ...  John Kershaw, President & CEO, Sysmex America Inc. has ... Secretary; Judy Bosko as Vice President of ...
... SCHAUMBURG, Ill. , July 1 ... today announced that the U.S. Food and Drug Administration ... sodium injection, USP. Heparin is a vital anticoagulant, preventing ... within the blood, routinely used in surgical and dialysis ...
Cached Medicine Technology:Sysmex America Announces Executive Leadership Changes 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 3FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 4
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil Valentine ... mile trek of the Appalachian Trail by stepping off Springer Mountain and heading ... , On July 26th Phil reached Connecticut and was greeted by friends and family. ...
(Date:7/31/2015)... CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will ... National Football League’s biggest day each year is the Super Bowl. In the two weeks ... takes place from the host venue. The 2016 Super Bowl game will mark the 50th ...
(Date:7/31/2015)... ... ... The 2nd annual Ride to Fight On will start and end near the ... to Fight On is a cycling fundraiser that benefits the West Cancer Center, a ... University of Tennessee Health Science Center. A health and wellness festival featuring food, music, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their flagship ... at the 2015 Vans US Open of Surfing, July 25 through August 2 in ... added sugar” on the market, is a natural choice given the Open’s commitment to ...
(Date:7/31/2015)... ... , ... Well-known for its unique pastries and delicious confections, Pastry Palace, a ... making life just a little bit sweeter for newlyweds. A family-owned business, the Pastry ... one. , The bakery provides a full line of custom wedding cakes. Brides can ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... Inc. (Nasdaq: OSTE ), a leader in ... announced today that the Company,s fourth quarter and full ... released Wednesday, March 4, 2009. The management team of ... Thursday, March 5, 2009, at 9:00 a.m. (EST) to ...
... March 2 At Aurora Health Care , finding ... businesses that rely on the health care provider for health ... well-being of its own employees, and that commitment recently was ... its local affiliate the Wellness Council of Wisconsin, presented its ...
... March 2 Speaker Nancy Pelosi released the ... Kathleen Sebelius as Secretary of the Department of Health ... bipartisan leader who has worked to expand health care ... prescription drugs. "Governor Sebelius, deep understanding of health care ...
... March 2 Nitinol Devices & Components, Inc. ... novel medical device anchoring technology from Phase One ... This anchoring technology integrates the superelastic material properties ... provide secure fixation and removability for minimally invasive ...
... cites association on GMPs and adverse event reportingWASHINGTON, ... the U.S. Government Accountability Office (GAO) of a ... supplements, the Natural Products Association (NPA) released the ... Seckman."The Natural Products Association appreciates having the opportunity ...
... 2 /PRNewswire-Asia-FirstCall/ -- China Nepstar,Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number of ... the fourth quarter and,fiscal year 2008 financial results ended ... 16, 2009. , The Company ...
Cached Medicine News:Health News:Aurora Wins Gold Well Workplace Award for Commitment to Employee Health and Well-Being 2Health News:NDC Completes Acquisition of Phase One Medical(R) Anchoring Technology 2Health News:Natural Products Association Comments on New GAO Report on Regulation of Dietary Supplements 2Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter and Fiscal 2008 Financial Results on March 16 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: